Suggestions
Amy Rudolph
Global Head, Evidence and Launch Excellence at Novartis
Amy Rudolph is a seasoned executive in the pharmaceutical industry, currently serving as the Vice President and Global Head of Evidence and Launch Excellence at Novartis, a position she held from November 2019 until February 2022. In this role, she was responsible for developing and implementing an integrated evidence strategy across over 30 development programs, facilitating rapid patient access and informed decision-making at product launches with a team of 45 professionals.1
Professional Background
Rudolph has extensive experience in drug development and commercialization, having worked in various leadership roles at Novartis since 2009. Prior to her role in Evidence and Launch Excellence, she served as the US Head of Health Economics and Outcomes Research, where she co-led the design of the US Clinical Development and Medical Affairs functions.1 Additionally, she played a pivotal role in enhancing access to treatments for heart failure patients through real-world evidence strategies that improved access for over 53 million patients in the United States.1
Before joining Novartis, Rudolph held significant positions at Pfizer, including Senior Clinical Director for the Apixaban Global Medical Team, where she contributed to cardiovascular metabolic and endocrine projects.1
Education
- Ph.D. in Biochemistry and Molecular Biology from Washington University in St. Louis (1991-1996)
- B.S. in Biology from the University of Missouri-Columbia (1987-1991)
- Completed postdoctoral fellowships at Washington University and the University of Michigan.12
Skills and Expertise
Rudolph's expertise spans various domains, including:
- Integrated evidence generation
- Patient access strategies
- Regulatory affairs across multiple regions (US, Japan, Canada)
- Clinical trial design and execution
- Real-world evidence leadership
She has been recognized for her transformative leadership style and her ability to collaborate effectively with diverse stakeholders, including healthcare systems, payers, and patient advocacy groups.1
In July 2023, Rudolph transitioned to become the Head of Global Medical Affairs at Boehringer Ingelheim, marking another significant step in her career within the pharmaceutical sector.1
